tldrdailynews.com logo

Weight Loss Drugs, Including Novo Nordisk's Ozempic, Linked to Eye Risks

1 min read
Source: Seeking Alpha
Weight Loss Drugs, Including Novo Nordisk's Ozempic, Linked to Eye Risks
Photo: Seeking Alpha
TL;DR Summary

The European Medicines Agency's safety committee has found that Novo Nordisk's weight loss and diabetes drug semaglutide can very rarely cause a serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION).

Topics:top-news#eu#health#novo-nordisk#semaglutide#side-effects#weight-loss
Share this article
  1. Novo Nordisk weight loss drug linked to eye disorder (NVO:NYSE)  Seeking Alpha
  2. Weight loss drugs linked to higher risk of eye damage in diabetic patients  The Guardian
  3. A kidney disease showdown, and eye risk linked to GLP-1s  statnews.com
  4. Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says  Reuters
  5. Semaglutide Linked to Age-Related Macular Degeneration Risk  MedPage Today

Reading Insights

Total Reads

0

Unique Readers

14

Time Saved

0 min

vs 1 min read

Condensed

63%

86 → 32 words

Want the full story? Read the original article

Read on Seeking Alpha